Aliskiren hemifumarate + Hydrochlorothiazide

Aliskiren is an orally active, potent, non-peptide and selective direct renin inhibitor used in the management of HTN. By inhibiting the enzyme renin, it prevents conversion of angiotensinogen into angiotensin I and therefore inhibits subsequent production of angiotensin II and aldosterone. Unlike ACE inhibitors and angiotensin II receptor antagonists which cause a compensatory rise in plasma renin activity, treatment with aliskiren decreases plasma renin activity and concentrations of angiotensin I angiotensin II and aldosterone .
 
Hydrochlorothiazide inhibits the reabsorption of Na and Cl in the distal tubules causing increased excretion of Na and water K and hydrogen ions.